The disease management approach to controlling asthma

Respiratory Medicine

Volumn 96, Issue SUPPL. 1, 2002, Pages

  Haahtela, T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; IRRITANT AGENT; PREDNISOLONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ACADEMIC ACHIEVEMENT; ASTHMA; AWARENESS; CELL INFILTRATION; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; ECONOMIC ASPECT; EMERGENCY; EOSINOPHIL; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITAL MANAGEMENT; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; LUNG FUNCTION TEST; MAST CELL; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PEAK EXPIRATORY FLOW; PERCEPTION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; SEASONAL VARIATION; SELF ESTEEM; SOCIAL ASPECT; SOCIAL STATUS; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; CHILD; INHALATIONAL DRUG ADMINISTRATION; PATIENT SATISFACTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; CHILD; HUMANS; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 0036483746     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1231     Document Type: Article

References (43)

1. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
2. Mahapatra P, Murray JL. Global burden of asthma, an estimate of incidence, remission, and prevalence. Report prepared for World Development Report 1993: Investing in Health. New York: Oxford University Press; 1993.
3. National Institutes of Health: National Heart Lung and Blood Institute. Asthma Management and Prevention. A Practical Guide For Public Health Officials and Health Care Professionals. Bethesda, MD: National Institutes of Health (publication 96-3659A); 1995.
4. National Institutes of Health: National Heart Lung and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health (publication No. 95-3659); 1995.
5. National Institutes of Health: National Heart Lung and Blood Institute. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health (publication No. 96-3659B); 1998.
6. Upton MN, McConnachie A, McSharry C et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321: 88-92.
7. Gellert AR, Gellert SL, Iliffe SR. Prevalence and management of asthma in a London inner city general practice. Br J Gen Pract 1990; 40: 197-201.
8. Chew FT, Goh DY, Lee BW. The economic cost of asthma in Singapore. Aust N Z J Med 1999; 29: 228-233.
9. Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999; 13: 281-286.
10. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322-1326.
11. Reijula K, Haahtela T, Klaukka T, Rantanen J. Incidence of occupational asthma and persistent asthma in young adults has increased in Finland. Chest 1996; 110: 58-61.
12. Taylor WR, Newacheck PR. Impact of childhood asthma on health. Pediatrics 1992; 90: 657-662.
13. Haahtela T. Early treatment of asthma. Allergy 1999; 54(Suppl. 49): 74-81.
14. National Institutes of Health: National Heart Lung and Blood Institute, National Asthma Education and Prevention Programme. Expert panel report II: Guidelines for the Diagnosis and Management of Asthma Bethesda, MA. National Institutes of Health (publication No. 97-4051); 1997.
15. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745.
16. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa J Clin Pathol 1960; 13: 27-33.
17. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806-817.
18. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-457.
19. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131: 599-606.
20. Jeffery PK, Godfrey RW, Ädelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890-899.
21. Haahtela T, Jarvinen M, Kava T et al. Comparison of a beta 2 agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392.
22. Haahtela T, Jarvinen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
23. Selroos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-1234.
24. Horn CR, Cochrane GM. Management of asthma in general practice. Respir Med 1989; 83: 67-70.
25. Blainey D. The cost of acute asthma - how much is preventable? Health Trends 1990; 22: 151-153.
26. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
27. Haahtela T, Klaukka T. Societal and healthcare benefits of early use of inhaled steroids (editorial). Thorax 1998; 53: 1005-1006.
28. Patel AM, Axes DM, Bartling SL, Guarderas JC. Practical considerations for managing asthma in adults. Mayo Clin Proc 1997; 72: 749-756.
29. Cochrane GM. Compliance in asthma Eur Respir Rev 1998; 8: 348-350.
30. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments Am J Respir Crit Care Med 1998; 157: S1-S53.
31. Beasley R, Pearce N, Crane J. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol 1999; 104: S18-S30.
32. O'Byrne PM, Cuddy L, Taylor DW, Birch S, Morris J, Syrtuite J. The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Respir J 1996; 3: 169-175.
33. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 115-137.
34. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
35. Woolcock AJ. The combined use of inhaled salmeterol and inhaled corticosteroids. Eur Respir Rev 1995; 5: 142-145.
36. Pauwels RA, Lofdahl C-G, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
37. Zetterström O, Buhl R, Mellem HS et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 95: 1-7.
38. Busse WW, Chervinsky P, Condemi J et al. Budesonide delivered by Turbuhaler® is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463.
39. Coutts JAP, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992; 67: 332-333.
40. Rand CS, Wise RA, Nides M et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146: 1559-1564.
41. Bender B, Milgrom H. Compliance with asthma therapy: a case for shared responsibility. J Asthma 1996; 33: 199-202.
42. Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998; 35: 455-472.
43. Haahtela T, Klaukka T, Koskela K, Erhola M, Laitinen LA. Asthma programme in Finland: a community problem needs community solutions. Thorax 2001; 56: 806-814.